23andMe Cleared to Report 41 More BRCA Mutations
Posted OnAugust 31, 2023 byThe U.S. Food and Drug Administration (FDA) has approved 23andMe, which makes at-home genetic tests, to report the presence of 41 more variants, or mutations, of the BRCA1 and BRCA2 genes that are linked to a higher risk of developing breast, ovarian, prostate, and pancreatic cancers.Read More…
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer
Posted OnAugust 29, 2023 byOn August 11, 2023, the Food and Drug Administration approved the fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.), with prednisone, for adult patients with deleterious or suspected (CONT)Read More…
FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer
Posted OnAugust 29, 2023 byOn June 20, 2023, the Food and Drug Administration approved talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).Read More…
Helicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer
Posted OnApril 27, 2023 byHelicobacter pylori infection is a well-known risk factor for gastric cancer. However, the contribution of germline pathogenic variants in cancer-predisposing genes and their effect, when combined with H. pylori infection, on the risk of gastric cancer has not been widely evaluated.Read More…
Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers
Posted OnMarch 29, 2023 bySeveral studies have reported the association of germline BRCA2 (gBRCA2) mutations with poor clinical outcomes in prostate cancer (PCa), but the impact of concurrent somatic events on gBRCA2 carriers survival and disease progression is unknown.Read More…
BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling
Posted OnOctober 31, 2022 byNewly diagnosed breast or ovarian cancer patients who carry common cancer-associated mutations have similar or better short-term survival rates than those with no mutations, researchers report.
New BRCA-targeting drug could offer hope in treating advanced prostate cancer
Posted OnOctober 14, 2022 byNewly diagnosed breast or ovarian cancer patients who carry common cancer-associated mutations have similar or better short-term survival rates than those with no mutations, researchers report.
Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response
Posted OnJuly 7, 2022 byEpigenetic changes to the promoter regions of BRCA1 appear to have a different effect on treatment response than genomic alterations in BRCA1 or BRCA2 in triple-negative breast cancer (TNBC) or ovarian carcinoma patients, new research suggests.Read More…
Health News – Why men should be tested for BRCA gene
Posted OnJune 28, 2022 byIt’s a genetic mutation that could put you at risk for certain cancers. While most people associate BRCA with breast cancer, the gene can carry risks for both men and women.
